Holen Sie sich die Stockscreener-App
75.09
1.23%
-1.075
Schlusskurs vom Vortag:
$76.17
Offen:
$75.44
24-Stunden-Volumen:
409.25K
Relative Volume:
0.27
Marktkapitalisierung:
$6.02B
Einnahmen:
$900.66M
Nettoeinkommen (Verlust:
$-453.20M
KGV:
-12.64
EPS:
-5.94
Netto-Cashflow:
$-274.19M
1W Leistung:
+3.80%
1M Leistung:
-3.17%
6M Leistung:
+59.80%
1J Leistung:
+62.92%
1-Tages-Spanne:
$74.05
$77.55
1-Wochen-Bereich:
$69.81
$77.55
52-Wochen-Spanne:
$35.95
$87.50
Ptc Therapeutics Inc Stock (PTCT) Company Profile
Firmenname
Ptc Therapeutics Inc
Sektor
Branche
Telefon
(908) 222-7000
Adresse
500 WARREN CORPORATE CENTER DRIVE, WARREN, NJ
Vergleichen Sie PTCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTCT
Ptc Therapeutics Inc
|
74.97 | 6.12B | 900.66M | -453.20M | -274.19M | -5.94 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.56 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.87 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
816.00 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
362.87 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.26 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ptc Therapeutics Inc Stock (PTCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-01 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-06-17 | Eingeleitet | Truist | Buy |
| 2025-05-09 | Hochstufung | BofA Securities | Neutral → Buy |
| 2025-05-07 | Hochstufung | Citigroup | Sell → Neutral |
| 2025-03-11 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Perform |
| 2024-12-13 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-03 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-09-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-08-26 | Fortgesetzt | UBS | Buy |
| 2024-05-20 | Hochstufung | Raymond James | Underperform → Mkt Perform |
| 2023-12-19 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-10-30 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2023-10-27 | Herabstufung | Citigroup | Neutral → Sell |
| 2023-10-06 | Herabstufung | Truist | Buy → Hold |
| 2023-09-18 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-09-15 | Herabstufung | Raymond James | Outperform → Underperform |
| 2023-03-17 | Eingeleitet | SVB Securities | Market Perform |
| 2022-12-14 | Eingeleitet | Goldman | Sell |
| 2022-09-12 | Eingeleitet | Jefferies | Buy |
| 2022-09-09 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-09-01 | Eingeleitet | Citigroup | Buy |
| 2022-04-04 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-10-18 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-29 | Hochstufung | RBC Capital Mkts | Underperform → Sector Perform |
| 2021-02-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-01-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-11-30 | Herabstufung | RBC Capital Mkts | Sector Perform → Underperform |
| 2020-10-30 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-07 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-25 | Eingeleitet | Raymond James | Outperform |
| 2020-04-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2020-02-20 | Herabstufung | Citigroup | Buy → Neutral |
| 2020-02-20 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-05-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2019-04-11 | Eingeleitet | Bernstein | Outperform |
| 2018-10-03 | Hochstufung | BofA/Merrill | Underperform → Neutral |
| 2018-10-01 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-07-19 | Eingeleitet | Credit Suisse | Outperform |
| 2018-06-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2018-04-04 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2018-01-29 | Fortgesetzt | RBC Capital Mkts | Sector Perform |
| 2017-11-16 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2017-10-26 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2017-10-09 | Herabstufung | JP Morgan | Neutral → Underweight |
Alle ansehen
Ptc Therapeutics Inc Aktie (PTCT) Neueste Nachrichten
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Morgan Stanley Is Bullish on PTC Therapeutics, Inc. (PTCT) as Small-Cap Biotech Outlook Improves - Insider Monkey
QRG Capital Management Inc. Takes Position in PTC Therapeutics, Inc. $PTCT - MarketBeat
Momentum Shift: What is International Money Express Incs market positionTrade Exit Report & AI Optimized Trading Strategy Guides - baoquankhu1.vn
First Week of September 18th Options Trading For PTC Therapeutics - Nasdaq
Does 2026 Revenue Guidance And Sephience Momentum Change The Bull Case For PTC Therapeutics (PTCT)? - Sahm
Discipline and Rules-Based Execution in PTCT Response - Stock Traders Daily
PTC Therapeutics projects FY26 product revenue between $700M to $800M - MSN
PTC Therapeutics reports $92.5M in Q4 Sephience revenue By Investing.com - Investing.com Nigeria
A Look At PTC Therapeutics (PTCT) Valuation As 2026 Revenue Guidance Reshapes Market Expectations - Sahm
Lobbying Update: $50,000 of PTC THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
Ptc Therapeutics CEO Klein sells $192k in shares By Investing.com - Investing.com Nigeria
Ptc Therapeutics CEO Klein sells $192k in shares - Investing.com
Utter, SVP at Ptc Therapeutics, sells $79k in shares By Investing.com - Investing.com Canada
Pauwels Eric, chief business officer of Ptc Therapeutics, sells $566k in shares - Investing.com Canada
PTC Therapeutics (NASDAQ:PTCT) VP Sells $180,330.02 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 4,602 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 881 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) EVP Lee Scott Golden Sells 866 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Sells $192,195.30 in Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CAO Christine Marie Utter Sells 1,034 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Shares Down 6.7%Here's Why - MarketBeat
PTC Therapeutics reports $92.5M in Q4 Sephience revenue - Investing.com
PTC Therapeutics, Inc. Provides Revenue Guidance for the Full Year 2026 - marketscreener.com
PTC Therapeutics Reports Preliminary 2025 Product Revenue, Sets 2026 Product Revenue Guidance - marketscreener.com
Ptc Therapeutics provides update at J.P. Morgan annual healthcare conference - marketscreener.com
Ptc Therapeutics Provides Update At J.P. Morgan Annual Healthcare Conference - TradingView — Track All Markets
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference - Yahoo Finance
PTC Therapeutics Inc (NASDAQ:PTCT) Emerges as a High-Growth Momentum Breakout Candidate - Chartmill
PTC Therapeutics, Inc. $PTCT Shares Purchased by SG Americas Securities LLC - MarketBeat
Market Outlook: Will PTC Therapeutics Inc stock sustain high P E ratios2025 EndofYear Setup & Expert Approved Trade Ideas - moha.gov.vn
PTC Therapeutics Inc (NASDAQ:PTCT) Combines Strong Growth with a Bullish Technical Setup - Chartmill
Is PTC Therapeutics Inc. stock a safe haven assetEarnings Risk Report & Growth Focused Stock Pick Reports - ulpravda.ru
PTC Therapeutics (NASDAQ:PTCT) EVP Sells $49,742.16 in Stock - MarketBeat
Neil Gregory Almstead Sells 1,026 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 3,016 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) Insider Sells 1,279 Shares of Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CAO Sells $95,650.75 in Stock - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) CFO Sells 2,139 Shares of Stock - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) Insider Eric Pauwels Sells 1,789 Shares - MarketBeat
PTC Therapeutics (NASDAQ:PTCT) CEO Matthew Klein Sells 5,149 Shares - MarketBeat
Insider Selling: PTC Therapeutics (NASDAQ:PTCT) VP Sells 4,879 Shares of Stock - MarketBeat
Stop Loss: Is GDRX stock vulnerable to regulatory risksBuy Signal & Daily Momentum Trading Reports - moha.gov.vn
PTC Therapeutics Executives Engage in Stock Transactions - TradingView — Track All Markets
Is PTC Therapeutics Inc. stock a defensive play in 20252025 Price Targets & Smart Investment Allocation Tips - ulpravda.ru
What dividend safety score for PTC Therapeutics Inc. stockQuarterly Market Summary & High Yield Stock Recommendations - ulpravda.ru
RBC Lowers Price Target on PTC Therapeutics to $87 From $91, Keeps Sector Perform Rating - marketscreener.com
PTC THERAPEUTICS, INC. (PTCT) - MSN
Lee Scott Golden Sells 1,340 Shares of PTC Therapeutics (NASDAQ:PTCT) Stock - MarketBeat
PTC Therapeutics, Inc. (NASDAQ:PTCT) Receives Average Rating of "Hold" from Analysts - MarketBeat
How Royalty Sale, Sephience Approval and CEO Share Sale At PTC Therapeutics (PTCT) Has Changed Its Investment Story - Sahm
Finanzdaten der Ptc Therapeutics Inc-Aktie (PTCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.31%
2.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):